These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 22018679

  • 1. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, Bruhn D.
    J Med Econ; 2012 Oct; 15(4):746-57. PubMed ID: 22443463
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012 Oct; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R.
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [Abstract] [Full Text] [Related]

  • 17. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.
    J Med Econ; 2012 Jul; 15 Suppl 2():1-5. PubMed ID: 22853443
    [Abstract] [Full Text] [Related]

  • 18. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC, Conner C, Hammer M.
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M, Harris K, Brackett A.
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.